Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
about
Advancements in the delivery of epigenetic drugsGene-Set Local Hierarchical Clustering (GSLHC)--A Gene Set-Based Approach for Characterizing Bioactive Compounds in Terms of Biological Functional GroupsSynergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Kinetic and thermodynamic characterization of C-N bond rotation by N-methylacetohydroxamic acid in aqueous media.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomasConserved Epigenetic Mechanisms Could Play a Key Role in Regulation of Photosynthesis and Development-Related Genes during Needle Development of Pinus radiataAntitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cellsVorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells.Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in HumansEpigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.New drug therapies in peripheral T-cell lymphoma.Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety.Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere.Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava.Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Inhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines.Recent advances in uveal melanoma treatment.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.Combination Phototherapy with a Histone Deacetylase Inhibitor and a Potent DNA-Binding Bibenzimidazole: Effects in Haematological Cell Lines
P2860
Q28088478-102793C2-BBA5-4CCB-9CE1-26C6FB707932Q28551050-E8674F33-D341-4C4F-ABA9-DCEF53583B46Q30541284-641A3297-6D27-4277-BA41-6271E7C295F2Q31007535-701170D6-48D1-4138-BD01-9D5BA37EE244Q33741828-4B66C093-8DA8-4454-BF69-FD1D0C15905CQ33876257-1DB7640D-D8A2-400E-934D-CFB65026DA9EQ34474267-F829E0B1-57F3-4DDB-B487-F1909483F90CQ35628039-0BFFE088-6076-47DD-8DAF-71B5566B0BEEQ36094595-936D9A2B-3CDE-4846-86DC-BC9685B7A267Q37160012-B16517EA-876C-43A6-9E33-0AA4BCD83B2BQ37224008-B4AEBA4F-50A1-471D-8C6E-C5A22E8A5755Q37249131-C286DA13-8A66-4A66-B7FE-C7A224A86307Q37737611-247BFE9B-E798-423E-A093-F7DAA3A74C72Q37854715-5CD05AB4-6A3D-4B8D-8E61-5F4E750ACF43Q38682574-AAF7A6C3-F8D9-4138-BCC2-2C348B058DB6Q38757478-2D1A6B2B-CE29-4673-BE2C-C2134CEEDA8DQ38789551-320C03B6-5604-4EC6-982A-E1742B37A781Q38937456-16E6C438-A556-48BE-85AD-DAF754DD0DDDQ39309547-9A47C56F-6B04-4DC5-A9B2-F29BD62D7902Q39539377-E824B334-3CEB-40A5-B40F-B69D5D1B305AQ40961675-40D653CE-8F37-41F0-B23E-E94EDDB598A1Q43244779-13971D0F-CF7F-4F04-B6B5-1B307CB56E14Q46155945-3734E29B-FB53-44E3-BF59-DD4E6C58A567Q47119995-F257AB34-1555-4E15-A30C-15327C6D7D00Q47325351-56E45E63-5F5D-4B18-8687-2790DAC2A856Q47571643-8B0768B5-ECC5-4A20-829C-81D0A3DCEF4BQ47633998-74DAD095-21C1-4D5F-8ADB-F5F7046DB780Q58698941-88254272-2586-475E-BFD5-8AE4F0E75964
P2860
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@ast
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@en
type
label
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@ast
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@en
prefLabel
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@ast
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@en
P2860
P3181
P356
P1476
Cancer biology: mechanism of a ...... histone deacetylase inhibitor
@en
P2093
P2860
P2888
P3181
P356
10.1038/SJ.BJC.6603463
P407
P433
P577
2006-12-12T00:00:00Z
P5875
P6179
1012838269